Enabling Unbiased Container Selection: Large-Volume IV & SC Drug Delivery Solutions
Day 2 Global Pharma Outlook Stage
07/10/2026 15:15 - 15:40pm
Contributors
Michael Weber : Head of Global Business Development for Polymer Solutions - SCHOTT Pharma AG & Co. KGaA
As biologics progress along their lifecycle, the transition from vial-based formats to advanced pre-filled systems becomes critical to enable patient-centric delivery and lifecycle value optimisation. As the shift from intravenous to subcutaneous delivery accelerates, large-volume subcutaneous (LVSC) biologics are redefining requirements for primary packaging. Enabling volumes beyond traditional limits demands solutions that ensure drug stability, patient safety, and seamless device integration.
SCHOTT Pharma addresses this need with advanced, ready-to-use (RTU) platform innovations, expanding both glass and polymer portfolios across syringes and cartridges. Designed for sensitive biologics and high-viscosity formulations, they combine low extractables, optimised silicone technology, and high break resistance with tight tolerances. Co-developed with leading device partners and aligned with standard fill-and-finish line requirements, these next-generation systems give pharmaceutical companies a decisive competitive edge - minimising development risk, accelerating time-to-market, and enabling reliable scale-up of LVSC therapies.